达格列净抑制铁调素并增加红细胞生成
这项前瞻性、随机、安慰剂对照研究纳入52例肥胖2型糖尿病患者,按1:1随机接受达格列净10 mg每日一次或安慰剂治疗12周。达格列净显著降低HbA1c,升高血红蛋白和血细胞比容,同时显著降低循环铁调素和铁蛋白,升高铁调素抑制物红铁酮并出现促红细胞生成素的一过性升高。作者结论认为,达格列净通过抑制铁调素及调节其他铁调控蛋白增加红细胞生成和血细胞比容。
要点
- 达格列净10 mg每日一次治疗12周可显著降低HbA1c并升高血红蛋白与血细胞比容。
- 达格列净显著降低循环铁调素和铁蛋白,升高红铁酮并出现促红细胞生成素一过性升高。
- 安慰剂组上述各项指标均无显著变化。
核心结论
- 作者结论认为,达格列净通过抑制铁调素和调节其他铁调控蛋白的机制增加红细胞生成和血细胞比容。
研究设计与样本
- 前瞻性、随机、安慰剂对照研究,单中心内分泌科开展,纳入52例肥胖2型糖尿病患者。
- 患者按1:1随机接受达格列净10 mg每日一次或安慰剂治疗12周,治疗前后采集血样并制备血清、血浆和单核细胞(MNC)。
- 主要结局指标为铁调素及其他造血因子。
主要发现
- 达格列净治疗后HbA1c显著下降,血红蛋白浓度和血细胞比容显著升高。
- 达格列净显著降低循环铁调素和铁蛋白浓度,同时显著升高铁调素抑制物红铁酮水平,并出现促红细胞生成素的一过性升高。
- 达格列净升高血浆转铁蛋白水平及MNC中转铁蛋白受体1和2的表达,铁细胞转运体铁转出蛋白表达无变化。
- 达格列净使MNC中缺氧诱导因子-1α表达下降,同时使其抑制物脯氨酰羟化酶-2表达升高。
- 安慰剂组上述各项指标均无显著变化。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Dapagliflozin and other SGLT2 inhibitors are known to increase hematocrit, possibly due to its diuretic effects and hemoconcentration. OBJECTIVE: Since type 2 diabetes is a proinflammatory state and since hepcidin, a known suppressor of erythropoiesis, is increased in proinflammatory states, we investigated the possibility that dapagliflozin suppresses hepcidin concentrations and thus increases erythropoiesis. DESIGN: Prospective, randomized, and placebo-controlled study. SETTING: Single endocrinology center. PATIENTS: Fifty-two obese type 2 diabetes patients. INTERVENTION: Patients were randomized (1:1) to either dapagliflozin (10 mg daily) or placebo for 12 weeks. Blood samples were collected before and after treatments and serum, plasma, and mononuclear cells (MNC) were prepared. MAIN OUTCOME MEASURE: Hepcidin and other hematopoietic factors. RESULTS: Following dapagliflozin treatment, there was a significant fall in HbA1c and a significant increase in hemoglobin concentration and hematocrit. Dapagliflozin treatment significantly reduced circulating hepcidin and ferritin concentrations while causing a significant increase in levels of the hepcidin inhibitor, erythroferrone, and a transient increase in erythropoietin. Additionally, dapagliflozin increased plasma transferrin levels and expression of transferrin receptors 1 and 2 in MNC, while there was no change in the expression of the iron cellular transporter, ferroportin. Dapagliflozin treatment also caused a decrease in hypoxia-induced factor-1α expression in MNC while it increased the expression of its inhibitor, prolyl hydroxylase-2. There were no significant changes in any of these indices in the placebo group. CONCLUSIONS: We conclude that dapagliflozin increases erythropoiesis and hematocrit through mechanisms that involve the suppression of hepcidin and the modulation of other iron regulatory proteins.
引用
- Ghanim H, Abuaysheh S, Hejna J, et al. Dapagliflozin Suppresses Hepcidin And Increases Erythropoiesis. J Clin Endocrinol Metab. 2020. PMID: 32044999. doi:10.1210/clinem/dgaa057
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。